Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioNexus Gene Lab Corp ( (BGLC) ) has shared an update.
In the third quarter of fiscal 2025, BioNexus Gene Lab Corp’s board authorized an evaluation of expanding its Chemrex subsidiary into contract development and manufacturing (CDMO) as part of a broader business rationalization, prompted by challenges in Chemrex’s legacy operations, a weaker business outlook, and the parent company’s push toward biotechnology-focused development. As part of an ongoing governance review of Chemrex aimed at strengthening oversight, compliance, and internal controls, the Chemrex board was reconstituted and appointed Matthew L. Barsing, a veteran of Malaysian public-sector digital initiatives and technology enterprises, as director and chairman; subsequently, on December 19, 2025, four Chemrex officers and directors resigned, and the company is still assessing the operational and governance implications of these departures without having reached any conclusions.
More about BioNexus Gene Lab Corp
BioNexus Gene Lab Corp, through its Chemrex Corporation Sdn. Bhd. subsidiary, operates in the chemicals and related services sector and is in the midst of shifting its strategic focus toward biotechnology-oriented development activities. Chemrex has historically run legacy operations that are now under review as the company considers expanding into contract development and manufacturing (CDMO) to better align with its evolving market and technological ambitions.
Average Trading Volume: 141,089
Technical Sentiment Signal: Sell
Current Market Cap: $7.6M
See more data about BGLC stock on TipRanks’ Stock Analysis page.